Intel stock spikes after report of possible US government stake
Robert E. Waltermire, Senior VP and Chief Pharma Development Officer at Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a $6.9 billion market cap company, recently sold shares of the company’s stock valued at $418,488. According to InvestingPro data, the stock has experienced significant volatility, declining nearly 10% in the past week despite maintaining strong liquidity metrics. The transactions, completed on February 28, involved the sale of 1,227 shares at weighted average prices ranging from $340.9857 to $341.5491 per share. Following these sales, Waltermire retains ownership of 3,728 shares in the company. InvestingPro analysis shows the company maintains a healthy current ratio of 6.1, with analysts setting price targets ranging from $236 to $539. Get access to 13 additional exclusive ProTips and comprehensive financial analysis with an InvestingPro subscription.
In other recent news, Madrigal Pharmaceuticals reported its fourth-quarter and full-year 2024 revenues, reaching $103 million and $180 million, respectively, which were at the high end of their preannounced range. Citi analyst David Lebowitz raised the price target for Madrigal to $469, citing strong sales of Rezdiffra, which outperformed market expectations for the third consecutive quarter. UBS also maintained a Buy rating with a $441 target, highlighting optimism in Madrigal’s commercial trajectory and growing demand. JMP Securities increased its price target to $443, following promising two-year data from the MAESTRO-NAFLD-1 trial, showing significant liver stiffness reduction in cirrhotic patients treated with Rezdiffra. H.C. Wainwright adjusted Madrigal’s price target to $405, maintaining a Buy rating, reflecting a positive outlook on the company’s growth prospects. TD Cowen reiterated a Buy rating with a $390 target, noting the significant reduction in liver stiffness in patients with compensated cirrhosis. Madrigal is also anticipating regulatory developments in Europe, with the European Medicines Agency expected to make a decision on Rezdiffra by mid-2025. These developments underscore Madrigal’s progress in addressing the unmet medical needs in the treatment of liver diseases.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.